Bausch Health Companies Inc. Common Stock (BHC)
5.9100
+0.00 (0.00%)
NYSE · Last Trade: Jan 26th, 8:58 AM EST
BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’stocktwits.com
Via Stocktwits · January 23, 2026
Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence.
Via The Motley Fool · December 10, 2025
Investors were obviously impressed with the company's latest acquisition.
Via The Motley Fool · December 1, 2025
Biggest Stock Movers Today, Dec. 1: BHC, SMR, & Morefool.com
Markets gave up ground to start the new month.
Via The Motley Fool · December 1, 2025
Carl Icahn's hedge fund Q3 portfolio reshuffle: $9.14B, concentrated, contrarian. Walked away from Bausch Health, added EchoStar.
Via Benzinga · November 17, 2025
Carl Icahn's empire, IEP, has collapsed 80% due to Hindenburg's short-selling attack. Icahn's net worth is down 75%.
Via Benzinga · November 6, 2025
Bausch Health (BHC) Q3 2025 Earnings Transcript
Via The Motley Fool · October 30, 2025
Via Benzinga · October 30, 2025
Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites.
Via Benzinga · October 27, 2025
Corporate insiders, often privy to the most granular details of their companies' health and future prospects, have been sending a clear signal to the market over the past 12-18 months: caution. A significant surge in insider selling, particularly pronounced in 2025, has overshadowed buying activity, pushing the U.S. market
Via MarketMinute · October 1, 2025
Via Benzinga · August 20, 2025
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Via Benzinga · August 16, 2025
Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names like CTRI and IFF.
Via Benzinga · August 15, 2025
Via Benzinga · August 15, 2025
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.
Via Benzinga · July 29, 2025
Via Benzinga · June 18, 2025
Top mid-cap stocks gain, led by energy companies due to increased oil prices from Middle East conflict. Oklo, Bausch Health, Quantum Computing among top performers.
Via Benzinga · June 15, 2025
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.
Via Benzinga · May 16, 2025
This disclosure comes days after the company announced a new “poison pill” plan to safeguard shareholders’ rights and prevent hostile takeovers.
Via Stocktwits · April 22, 2025